The Conversation (0)
ImpediMed Announces First Patient Enrolled at Scripps Memorial Hospital
Oct. 15, 2018 08:50AM PST
Medical Device InvestingImpediMed (ASX:IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), announces that the first patient has been enrolled in its 200-patient Heart Failure (HF) trial now being conducted at Scripps Memorial Hospital, San Diego, CA. As quoted in the press release: With the first patient …
ImpediMed (ASX:IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), announces that the first patient has been enrolled in its 200-patient Heart Failure (HF) trial now being conducted at Scripps Memorial Hospital, San Diego, CA.
As quoted in the press release:
With the first patient in this at-home HF trial now enrolled, the study will follow patients at-home for 45 days post discharge from a HF-related hospital admission. The study is designed to demonstrate the extent to which changes in SOZO® BIS measurements preempt patient-reported symptoms of HF that lead to hospital readmissions. Data has shown 25 percent of patients admitted for HF will be readmitted in <30 days. Earlier identification of fluid overload allows for treatment changes which have resulted in significant reduction of costly re-hospitalization.
A.J. Accardi, M.D. from Scripps Memorial Hospital in San Diego states, “We are very excited about enrolling the first patient in this new 200-patient trial with ImpediMed. SOZO has the potential to significantly improve the quality of life for heart failure patients by enabling them to remotely monitor their fluid status so that clinical intervention can take place as soon as possible. This early intervention is critical to helping prevent the occurrence of rehospitalization.”